27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
The FDA has granted Orphan Drug Designation to RegenXbio Inc's (NASDAQ:RGNX) RGX-202, potential one-time gene therapy for Duchenne muscular dystrophy (Duchenne).
- Duchenne is a genetic disorder characterized by progressive muscle degeneration and weakness due to the alterations of a protein called dystrophin that helps keep muscle cells intact.
- RGX-202 is designed to deliver optimized microdystrophin transgene with a unique C-terminal domain and a muscle-specific promoter to support targeted therapy for improved resistance to muscle damage associated with Duchenne.
- RGX-202 uses RegenXbio's proprietary NAV AAV8 vector.
- The Company expects to submit an Investigational New Drug (IND) application to the FDA for RGX-202 by the end of 2021.
- Related content: Benzinga's Full FDA Calendar.
- Price Action: RGNX shares are up 0.66% at $33.73 during the market session on the last check Monday.
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!